Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)

Inclusion Criteria:

• Patients with a physician-confirmed diagnosis of ADHD per Diagnostic and StatisticalManual of Mental Disorders (DSM-5) criteria and the health care practitioner (HCP) hasmade the decision to prescribe an extended-release methylphenidate (ER MPH) product tothe patient for potential improvement of symptoms throughout and later in the day,independent of this study.
• Patient must be 12 years of age or older.
• Patient must be eligible to receive Adhansia XR or osmotic- release oral deliverysystem methylphenidate ([OROS MPH] or Concerta) according to the US product labels; apatient must be eligible and willing to receive either drug, as randomization willassign them to a specific treatment group. Patient may be treatment-experienced ornaïve to pharmacological therapy for ADHD, so long as all inclusion and no exclusioncriteria are met.
• Patient must be willing to take only the assigned study medication per HCPinstructions based on FDA label guidance for treatment of their ADHD for the first 2months of the study (i.e. full titration period). Patients should not be on any othermedication, or starting any new non-medication treatment, proven to have effect onADHD in the first two months of the study.

Exclusion Criteria:

• Concurrent participation in an investigational study in which patient assessmentand/or treatment may be dictated by a protocol.
• Patients with a true allergy to methylphenidate (MPH), amphetamine (AMP), orsympathomimetic amines, history of serious adverse reactions to MPH or AMP or be knownto be non-responsive to MPH or AMP treatment.
• Patient is currently stable on their ADHD treatment regimen.
• Female patients of child bearing potential who are pregnant, planning on becomingpregnant or breastfeeding.
• Patient with any known conditions that are contraindicated for either Adhansia XR orOROS MPH (or Concerta) use, as documented in the US Full Prescribing Information,including patients with any known serious structural cardiac abnormalities,cardiomyopathy, serious heart arrhythmias, or coronary artery disease.
• Patients with a known sensitivity to the food dye tartrazine (Federal Food, Drug, andCosmetic Yellow No. 5).
• Suicidal Ideation
• The Columbia-Suicide Severity Rating Scale (C-SSRS) will be administered atscreening and at Month-2, Month-4, and Month-6, but also depends on the judgmentof the HCP.
• Inability or unwillingness of the patient (or parent/guardian if patient is a minor)to complete the study-required electronic questionnaires and provide requiredinformation through electronic means.